Abstract 5501
Background
Head and neck squamous cell carcinoma (HNSCC) patients with a significant tobacco smoking history have a poor prognosis compared to never smokers. We hypothesize the poor prognosis in tobacco smokers with HNSCC is, at least in part, due to ongoing suppression of immune response and that understanding of deregulated signals in each step may provide insights to improve clinical outcomes of HNSCC patients.
Methods
We characterized the tumor immune microenvironment (TIM) of HNSCC in a retrospective cohort of 177 current, former, and never smokers. Tumors were subjected to analysis of CD3, CD8, FOXP3, PD-1, PD-L1, and pan-cytokeratin by multiplex immunofluorescence, whole exome sequencing, and RNA sequencing. The immune markers were measured in the tumor core (TC), tumor margin (TM), and stroma (S).
Results
Our data indicate that current smokers have significantly lower numbers of CD8+ cytotoxic T-cells and PD-L1+ cells compared to never- and former-smokers. While tumor mutation burden and mutant-allele tumor heterogeneity score do not associate with smoking status, gene-set enrichment analyses reveal significant suppression of IFN-α and IFN-γ response pathways in current smokers. Gene expression of canonical IFN-response chemokines of the CXCL9, CXCL10, CXCL11/CXCR3 axis are lower in current smokers than in former smokers suggesting decreased immune cell migration to the tumor site.
Conclusions
These results indicate that active tobacco use in HNSCC has an immunosuppressive effect through inhibition of tumor infiltration of cytotoxic T-cells likely as a result of suppression of IFN response pathways. Our study highlights the importance of understanding the interaction between smoking and TIM in light of emerging immune modulators for cancer management and the importance of smoking cessation during treatment with immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The James and Esther King Biomedical Research Grant.
Disclosure
C.H. Chung: Honoraria (self): bristol myers squibb; Honoraria (self): astrazeneca; Honoraria (self): Lilly; Honoraria (self): CUE Biopharma. J. Conejo-Garcia: Honoraria (self): Compass Therapeutics; Honoraria (self): Anixa Biosciences. R. Slebos: Spouse / Financial dependant: Bristol Myers Squibb; Spouse / Financial dependant: AstraZeneca ; Spouse / Financial dependant: CUE Biopharma; Spouse / Financial dependant: Lilly Oncology. All other authors have declared no conflicts of interest.
Resources from the same session
2600 - Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): a long-term overall survival (OS) and safety update from the Phase III IMvigor211 study
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3598 - Three-Year Follow-Up From the Phase 3 KEYNOTE-045 Trial: Pembrolizumab (Pembro) Versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer (UC)
Presenter: Andrea Necchi
Session: Poster Display session 3
Resources:
Abstract
2382 - First Report of Efficacy and Safety From a Phase 2 Trial of Tislelizumab, an Anti-PD-1 Antibody, for the Treatment of PD-L1+ Locally Advanced or Metastatic Urothelial Carcinoma (UC) in Asian Patients
Presenter: Dingwei Ye
Session: Poster Display session 3
Resources:
Abstract
2388 - Quality of Life of Metastatic Urothelial Cancer (mUC) Patients Treated with Enfortumab Vedotin (EV) Following Platinum-Containing Chemotherapy and a Checkpoint Inhibitor (CPI): Data from EV-201 Cohort 1
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
3748 - Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
1126 - Validation of the VIO prognostic index in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors
Presenter: Rafael Morales Barrera
Session: Poster Display session 3
Resources:
Abstract
3693 - Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer
Presenter: Justin Matulay
Session: Poster Display session 3
Resources:
Abstract
4840 - Analysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients (pts) with metastatic urothelial carcinoma (mUC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
1221 - Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
Presenter: Jean Hoffman-censits
Session: Poster Display session 3
Resources:
Abstract
1715 - National Small Cell Bladder Cancer Audit: Results from 26 UK institutions
Presenter: Caroline Chau
Session: Poster Display session 3
Resources:
Abstract